LIQUIDIA CORPORATION (LQDA) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 450.91M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $450.91M | (m) | (m) |
| 2026-03-31 | (m) | $288.06M | (m) | (m) |
| 2025-12-31 | (m) | $158.32M | (m) | (m) |
| 2025-09-30 | (m) | $69.22M | (m) | (m) |
| 2025-06-30 | (m) | $19.32M | (m) | (m) |
| 2025-03-31 | (m) | $14.14M | $5.93M | (m) |
| 2024-12-31 | (m) | $14.00M | $5.88M | (m) |
| 2024-09-30 | (m) | $15.61M | $5.52M | (m) |
| 2024-06-30 | (m) | $14.84M | $4.52M | (m) |
| 2024-03-31 | (m) | $15.97M | $3.70M | (m) |
| 2023-12-31 | (m) | $17.49M | $2.89M | (m) |
| 2023-09-30 | (m) | $18.32M | $2.59M | (m) |
| 2023-06-30 | (m) | $17.80M | $2.76M | (m) |
| 2023-03-31 | (m) | $16.94M | $2.82M | (m) |
| 2022-12-31 | (m) | $15.94M | $2.86M | (m) |
| 2022-09-30 | (m) | $13.79M | $2.89M | (m) |
| 2022-06-30 | (m) | $13.80M | $3.04M | (m) |
| 2022-03-31 | (m) | $13.26M | $3.02M | (m) |
| 2021-12-31 | (m) | $12.85M | $3.02M | (m) |
| 2021-09-30 | (m) | $10.38M | (m) | (m) |
| 2021-06-30 | (m) | $7.20M | (m) | (m) |
| 2021-03-31 | (m) | $3.82M | (m) | (m) |
| 2020-12-31 | (m) | $739.63K | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $8.07M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |